Antibodies for Cancer Therapy



Antibodies have great specificity and potency to be directed against cancer. The latest wave of novel antibody designs leverages our current knowledge of the tumor microenvironment and immune cell populations and our understanding of biology for selective targeting. Don’t miss the Ninth Annual Antibodies for Cancer Therapy conference for a meeting of the great thought leaders in the field to share creative ideas and advance clinical progress.

Final Agenda

Scientific Advisory Board

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital

Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

Horacio G. Nastri, PhD, Senior Director, Antibody Biotherapeutics, Incyte Corporation 


Recommended Short Course(s)*

SC2: Translational Biotherapeutic Development Strategies Part 1: Discovery, Molecular Assessment and Early Stage Development

Juan Carlos Almagro, PhD, Founder and Director, GlobalBio, Inc.

Zhiqiang An, PhD, Professor, Chemistry; Director, Texas Therapeutics Institute, University of Texas Health Science Center at Houston

Gadi Bornstein, PhD, Senior Director, Biologics Discovery, TESARO, Inc.

SC7: Translational Biotherapeutic Development Strategies Part 2: Analytical and Clinical Considerations

Zhiqiang An, PhD, Professor, Chemistry; Director, Texas Therapeutics Institute, University of Texas Health Science Center at Houston

Scott L. Klakamp, PhD, Senior Director & Head, Biophysics, Biologics Development Sciences, Janssen BioTherapeutics

Liming Liu, PhD, Senior Principal Scientist, Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM), Merck Research Laboratories

An Song, PhD, Senior Vice President, Development Sciences, Immune-Onc Therapeutics, Inc.


*Separate registration required.


7:00 am Registration and Morning Coffee


8:30 Chairperson’s Opening Remarks

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital

8:40 Using Tumor Reactive mAb and IL2 to Sequentially Engage Innate and Adaptive Anti-Tumor Immunity

Sondel_PaulPaul M. Sondel, MD, PhD, Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics, and Director of Research, UW Division of Pediatric Hematology, Oncology and BMT, UW Carbone Cancer Center and American Family Children’s Hospital, University of Wisconsin

We are developing immunotherapy regimens to eliminate advanced-large immunologically “cold” tumors in immunocompetent mice. In some models, local radiation therapy combined with intratumoral tumor-reactive mAb+IL2 can eradicate large established tumors with T-cell memory, enabling the tumor to be an in situ vaccine. In mice with two tumors of the same type, immunosuppression from the distant tumor can be overcome by inhibition of Treg cells. Clinical translation is being pursued.

9:10 Role of HLA Antigen Presentation in Resistance to Immune Checkpoint Blockade

Hodi_StephenF. Stephen Hodi, MD, Professor, Medicine, Harvard Medical School; Professor, Medical Oncology, Dana-Farber Cancer Institute; Sharon Crowley Martin Chair, Melanoma, Dana-Farber Cancer Institute

Tumor mutational burden correlates with response to immune checkpoint blockade in multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain clinical utility. Here we uniformly analyzed whole-exome sequencing (WES) of 249 tumors and matched normal tissue from patients with clinically annotated outcomes to immune checkpoint therapy including radiographic response across multiple cancer types to examine additional tumor genomic features that contribute to selective response. Our analyses identified genomic correlates of response beyond mutational burden, including somatic events in individual driver genes, certain global mutational signatures, and specific HLA-restricted neoantigens. However, these features were often interrelated, highlighting the complexity of identifying genetic driver events that generate an immunoresponsive tumor environment. This study lays a path forward in analyzing large clinical cohorts in an integrated and multifaceted manner to enhance the ability to discover clinically meaningful predictive features of response to immune checkpoint blockade.

9:40 The Next Era of Cancer Therapeutics: Defining Biologic Problems, Engineering Solutions

Chen_DanielDaniel Chen, MD, PhD, CMO, IGM Biosciences

The opportunity for therapeutics that turn on or off a singular target has largely been explored. However, advancements in our understanding of cancer, immune biology, and protein/cellular engineering approaches begin to define what seemed like science fiction only a few years ago. The spatial temporal coordination of modulating different biologies and cell types within emerging cancer immunotherapy will be explored.

10:10 Networking Coffee Break


10:45 Chairperson’s Remarks

Soldano Ferrone, MD, PhD, Division of Surgical Oncology, Surgery, Massachusetts General Hospital

10:50 Genetic Alteration of the Bispecific Antibody Platform to Create Trispecific NK Cell Engagers (TriKes) Targeting B7-H3

Vallera_DanielDaniel A. Vallera, PhD, Lion Scholar and Professor, Director, Section on Molecular Cancer Therapeutics; Professor of Therapeutic Radiology, University of Minnesota Masonic Cancer Center

TriKEs are trispecific natural killer (NK) cell engagers and novel immunotherapeutic drugs. A first-generation TriKE consisting of two antibody scFV fragments each recognizing NK cells and AML cells was cross-linked with cytokine IL-15. Recently, TriKes have been vastly improved by conversion of the scFVs to camelid framework. We will discuss xenograft studies of first generation TriKE, testing of the improved camelid TriKE, and clinical batch status. We will also discuss TriKEs targeting B7-H3 for solid tumor therapy.

11:20 Past, Present and Future of Omburtamab for the Treatment of B7H3(+) Tumors

Ahmed_MahiuddinMahiuddin Ahmed, PhD, CSO, Y-mAbs Therapeutics

Omburtamab is a murine IgG1 that is under clinical investigation for compartmental radioimmunotherapy of B7-H3(+) tumors. Omburtamab labeled with 131- or 124-Iodine can be delivered directly into 1) the brain ventricles for pediatric neuroblastoma patients with CNS/leptomeningeal metastases, 2) the pons for diffuse intrinsic pontine glioma, and 3) the peritoneum for desmoplastic small round cell tumors. New versions of omburtamab (177-Lutetium conjugate and humanized sequence) are currently under pre-clinical development.

11:50 MGC018: A Duocarmycin-Based Antibody Drug Conjugate Targeting B7-H3

Loo_DerykDeryk Loo, PhD, Director, Targeted Therapeutics and Site Operations, MacroGenics, Inc.

MGC018 is an ADC comprised of the cleavable linker-duocarmycin payload, valine-citrulline-seco DUocarmycin hydroxyBenzamide Azaindole (DUBA), conjugated to a humanized anti-B7-H3 antibody through interchain disulfides. MGC018 demonstrated antitumor activity in vivo toward B7-H3-expressing tumor xenografts at clinically relevant doses. MGC018 was tolerated in cynomolgus monkeys at exposure levels exceeding those required for antitumor activity. Our findings support clinical development of MGC018 to evaluate its potential as a therapeutic for B7-H3-expressing solid cancers.

12:20 pm Streamlined Discovery and Production of Therapeutic Antibodies

Meelis Kadaja, PhD, MBA, Director of Business Development, Icosagen Cell Factory

We take advantage of the universal HybriFree antibody discovery engine to efficiently discover therapeutic antibodies by direct cloning from B-cells of immunized rabbit, chicken, human, or dog. HybriFree method is further powered by our patented QMCF expression platform to produce high-quality recombinant protein antigens and antibodies cost-effectively for pre-clinical research (including afucosylated antibodies for enhanced ADCC). Technologies and case studies will be presented and discussed.

12:50 Luncheon Presentation I to be Announced


eurofins1:20 Luncheon Presentation II to be Announced 

1:50 Session Break

2:20 Problem-Solving Breakout Discussions - Click here for details

3:20 Networking Refreshment Break


4:00 Chairperson’s Remarks

Rakesh Dixit, PhD, DABT, Vice President, R&D, Global Head, Biologics Safety Assessment, Translational Sciences, MedImmune


4:10 Vision for How Immunotherapy Will Shape Future of Cancer Care

Leena Gandhi, MD, PhD, Vice President, Immuno-Oncology Medical Development, Lilly Oncology

Immunotherapy is considered by many as a pillar of cancer care today, but in many ways we have only scratched the surface. Our knowledge and understanding of the complexities of immunotherapy and its mechanisms continue to evolve. The future of cancer care will be defined by our ability to systematically identify and implement opportunities for combination therapy to improve and standardize patient response.


4:55 The Lassa Virus Glycoprotein: Stopping a Moving Target

keynote-headshot-hastie-400x400Kathryn Hastie, PhD, Staff Scientist, Immunology and Microbiology, The Scripps Research Institute

Lassa virus causes ~5000 deaths from viral hemorrhagic fever every year in West Africa. The trimeric surface glycoprotein, termed GPC, is critical for infection, is the target for neutralizing antibodies, and a major component of vaccines. Structural analysis of Lassa GPC bound to antibodies from human survivors reveals a major Achilles heel for the virus and provides the needed template for development of immunotherapeutics and improved vaccines.

5:40 Welcome Reception in the Exhibit Hall with Poster Viewing

7:15 End of Day


8:00 am Registration and Morning Coffee


8:25 Chairperson’s Remarks

Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

8:30 A Two-in-One Approach to Target Solid Tumors – CAR T-Cells and Checkpoint Blockade

Adusumilli_PrasadPrasad S. Adusumilli, MD, FACS FCCP, Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center (CTC), Memorial Sloan-Kettering Cancer Center; Associate Professor, Cardiothoracic Surgery, Weill Cornell Medical Center

The presentation will focus on cell-intrinsic and extrinsic methods in overcoming checkpoint blockade in cellular immunotherapy.

9:00 Immunotoxins Targeting Mesothelin for Cancer Therapy

Hassan_RaffitRaffit Hassan, MD, Senior Investigator & Chief, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH

Mesothelin is a tumor differentiation antigen with limited expression on normal mesothelial cells but is highly expressed in many cancers. LMB-100 is an anti-mesothelin immunotoxin (anti-mesothelin Fab linked to PE toxin) currently in clinical trials for treating patients with malignant mesothelioma and pancreatic cancer. Our efforts are focused on improving anti-tumor efficacy of LMB-100 by decreasing its immunogenicity as well as combination studies with chemotherapy and immune checkpoint inhibitors.

9:30 Pancreatic Cancer Therapy with Mesothelin-Redirected Chimeric Antigen Receptor T Cells and Overcoming Barriers to their Efficacy

O'Hara_MarkMark O’Hara, MD, GI Malignancy Oncologist, University of Pennsylvania

Pancreatic ductal adenocarcinoma (PDA) is characterized by its highly immunosuppressive tumor microenvironment (TME) that limits T cell infiltration and induces T cell hypofunction. Delivery of mesothelin-redirected chimeric antigen receptor T cell (meso-CAR T cell) therapy in pancreatic cancer patients has been feasibile and safe, and though some efficacy has been demonstrated, antitumor activity remains modest. Our efforts are focused on improving efficacy of meso-CAR T cells, including tumor-directed infusion of meso-CAR T cells, genome-editing of CAR T cells, and combining meso-CAR T cells with an oncolytic adenovirus expressing TNF-α and IL-2.

10:00 Coffee Break in the Exhibit Hall with Poster Viewing


10:45 Chairperson’s Remarks

Horacio G. Nastri, PhD, Senior Director, Antibody Biotherapeutics, Incyte Corporation

10:50 Preclinical Validation of B-Cell Maturation Antigen (BCMA) as a Target for T-Cell Immunotherapy of Multiple Myeloma

Bu_DexiuDexiu Bu, MD, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institute for Biomedical Research

Chimeric antigen receptor (CAR) targeting BCMA is an attractive approach for treating multiple myeloma. We screened a set of novel, fully human scFv binding domains to BCMA. Using a series of in vitro and pre-clinical in vivo studies, we identified a scFv with high specificity for BCMA and robust anti-myeloma activity. This BCMA-specific CAR is currently being evaluated in a Phase Ib clinical study in relapsed and refractory MM patients.

11:20 Tumor-Specific Carbohydrate Antigens as Preferable Targets for Novel Bispecific Immunotherapeutics Targeting Solid Tumors

Jakel_AnikaAnika Jäkel, PhD, Director, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH

Carbohydrates on the surface of cancer cells represent preferable targets for bispecifics due to their unique tumor-specificity with lack of inaccessibility on normal tissues and broad indication coverage. We demonstrate that carbohydrates are valuable targets for different bispecific approaches by creating a carbohydrate-targeted IL-15-based immunocytokine and a bispecific T-cell engager. Both molecules are able to stimulate an array of effector cell responses in vitro and in vivo and are suitable agents for mono or combinatorial therapy of solid tumors.

11:50 Disrupting the CD47-SIRPα Anti-Phagocytic Axis by a Humanized Anti-CD47 Antibody is an Efficacious Treatment for Malignant Pediatric and Adult Brain Tumors

Gholamin_ShararehSharareh Gholamin, MD, PhD Candidate, Division of Biology and Biological Engineering, California Institute of Technology

Morbidity and mortality associated with pediatric malignant primary brain tumors remain high in the absence of effective therapies. Macrophage-mediated phagocytosis of tumor cells via blockade of the anti-phagocytic CD47-SIRPα interaction using anti-CD47 antibodies has shown promise in preclinical xenografts of various human malignancies. We demonstrate the effect of a humanized anti-CD47 antibody, Hu5F9-G4, on five aggressive and etiologically distinct pediatric brain tumors: group 3 medulloblastoma (primary and metastatic), atypical teratoid rhabdoid tumor, primitive neuroectodermal tumor, pediatric glioblastoma, and diffuse intrinsic pontine glioma. Hu5F9-G4 demonstrated therapeutic efficacy in vitro and in vivo in patient-derived orthotopic xenograft models. Intraventricular administration of Hu5F9-G4 further enhanced its activity against disseminated medulloblastoma leptomeningeal disease. Notably, Hu5F9-G4 showed minimal activity against normal human neural cells in vitro and in vivo, a phenomenon reiterated in an immunocompetent allograft glioma model. Thus, Hu5F9-G4 is a potentially safe and effective therapeutic agent for managing multiple pediatric central nervous system malignancies.

12:20 Luncheon Presentation I to be Announced

OmniAb Ligand_Pharmaceuticals 12:50 Luncheon Presentation II to be Announced

1:20 Ice Cream Break in the Exhibit Hall with Poster Viewing


2:00 Chairperson’s Remarks

Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

2:05 Anti-BCMA Recombinant Immunotoxins Are Highly Active Agents for Myeloma Therapy

Pastan_IraIra H. Pastan, MD, Co-Chief, Laboratory of Molecular Biology; NIH Distinguished Investigator; Head, Molecular Biology Section

BCMA is highly expressed in myeloma cells and is an excellent target for myeloma therapy. We produced mAbs that recognize BCMA, but not other family members, and used them to make RITs that kill myeloma cell lines and patient cells. To evaluate anti-tumor activity, we prepared H929 cells expressing luciferase. Untreated mice survived 40 days, whereas treated mice were tumor-free at 90 days.

2:35 Immune-Based Therapies in AML/MDS

Daver_NavalNaval G. Daver, MD, Associate Professor, Leukemia Department, MD Anderson Cancer Center

3:05 Antibody Protein Sequencing with Mass Spectrometry

Xie_MingjieMingjie Xie, CEO, Rapid Novor, Inc.

Many applications in antibody engineering require the direct sequencing of antibody proteins. At Rapid Novor ( we have developed a robust workflow and routinely sequenced antibody proteins. Here we share the success experiences, examine common mistakes novices make, and present our practices to ensure the correctness of every amino acid.

AbMaxBiotechnology 3:20 Presentation to be Announced 

3:35 Refreshment Break in the Exhibit Hall with Poster Viewing


Chairperson’s Remarks

Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

4:25 Development of Next Generation Immune Modulators

Hoet_ReneRené Hoet, PhD, CSO, Imcheck Therapeutics

Imcheck Therapeutics, an emerging biotech, develops antibodies to novel targets in immuno-oncology and potentially autoimmune diseases. The presentation will cover the progress of development of two first-in-class therapeutic antibodies (an anti-BLTA and an anti-BTN3) that have a positive effect on proliferation of gamma delta T cells and inhibition of tumor growth that are developed towards the clinic in 2020. In addition, the company identified an additional set of novel targets that are in the antibody validation stage for treatment in immune-oncology and potentially autoimmunity.

4:55 Phase I CD123 CAR T Cell Trial in Adults with Relapsed/Refractory AML

Budde_ElizabethElizabeth Budde, MD, PhD, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

5:25 Strategies and Challenges for Targeting CD47 to Enhance Antitumor Immunity

Roberts_DavidDavid D. Roberts, PhD, Senior Investigator, Head, Biochemical Pathology Section, Laboratory of Pathology, CCR, NCI

The resistance of many cancers to current immune checkpoint inhibitors might be overcome by identifying additional checkpoint molecules that enable tumors to evade immune surveillance. CD47 is a ubiquitously expressed receptor for thrombospondin-1 and the counter-receptor for signal-regulatory protein-α. The latter interaction prevents innate immune clearance of tumor cells that express elevated levels of CD47. Preclinical and clinical development of antibodies and other methods for targeting CD47 will be discussed.

5:55 End of Antibodies for Cancer Therapy: Driving Breakthrough Therapies

5:30 Registration for Dinner Short Courses

Recommended Short Course*

SC10: CAR T-Cell Therapy for Solid Tumors


*Separate registration required.

* 活動內容有可能不事先告知作更動及調整。

Choose your language

Premier Sponsors